Trigon acted as Joint Global Coordinator and Joint Bookrunner (together with mBank) for Bioceltix S.A.’s PLN 63 million Accelerated Bookbuilding (ABB).

Trigon, together with mBank S.A., successfully completed a PLN 63 million Accelerated Bookbuilding (ABB) for Bioceltix S.A., a biotechnology company listed on the Warsaw Stock Exchange. The offering included the sale of 727,785 existing shares, representing 14.8% of the company’s share capital, at PLN 87 per share. Notably, 83% of the transaction proceeds will be allocated to Bioceltix through a new share issuance, supporting the construction of one of the world’s largest manufacturing facilities for stem cell–based veterinary biological medicines. The transaction attracted strong investor demand, supported by Bioceltix shareholders Alternative Solution ASI and Kvarko Group ASI, who committed the majority of proceeds to subscribe for new shares at the same price. This marks another successful equity financing round for Bioceltix, continuing Trigon’s long-term cooperation with the company and highlighting our expertise in capital market transactions for innovative life sciences businesses.